Applied Finance Capital Management LLC Cuts Stock Holdings in United Therapeutics Corporation $UTHR

Applied Finance Capital Management LLC trimmed its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,093 shares of the biotechnology company’s stock after selling 39 shares during the period. Applied Finance Capital Management LLC’s holdings in United Therapeutics were worth $314,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Nordea Investment Management AB raised its stake in shares of United Therapeutics by 50.5% during the second quarter. Nordea Investment Management AB now owns 10,914 shares of the biotechnology company’s stock valued at $3,146,000 after acquiring an additional 3,664 shares during the last quarter. Aware Super Pty Ltd as trustee of Aware Super raised its stake in shares of United Therapeutics by 11.7% during the second quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 106,484 shares of the biotechnology company’s stock valued at $30,598,000 after acquiring an additional 11,172 shares during the last quarter. Ritholtz Wealth Management raised its stake in shares of United Therapeutics by 30.3% during the second quarter. Ritholtz Wealth Management now owns 1,075 shares of the biotechnology company’s stock valued at $309,000 after acquiring an additional 250 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in shares of United Therapeutics by 267.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,654 shares of the biotechnology company’s stock valued at $1,050,000 after acquiring an additional 2,660 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in shares of United Therapeutics by 60.0% during the second quarter. Sequoia Financial Advisors LLC now owns 1,067 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 400 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold 292,435 shares of company stock valued at $118,956,307 in the last ninety days. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $433.34 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48. The company has a 50 day simple moving average of $385.69 and a two-hundred day simple moving average of $328.04. The company has a market capitalization of $19.55 billion, a price-to-earnings ratio of 16.91, a P/E/G ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the business posted $5.85 EPS. United Therapeutics’s revenue for the quarter was up 11.7% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on UTHR shares. UBS Group upped their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Morgan Stanley increased their price target on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Wells Fargo & Company increased their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $457.21.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.